Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
In order to evaluate the risk of second malignances(SM) during treatment with tyrosine kinase inhibitors(TKIs), a retrospective study is designed among chronic myeloid leukemia (CML) patients. The result suggested that patients with CML treated with TKIs had the higher relative incidence of SM when compared with the expected incidence among the general Chinese population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Xiu-Feng Yin, Jing-Han Wang, Xia Li, Meng-Xia Yu, Zhi-Xin Ma, Jie Jin Tags: Original Study Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Lymphoma | Men | Myeloma | Study